Disclosure: L. Orioli: None. S. Samaras: None. P. Lause: None. M. de Barsy: None. J.M. Thissen: None. A. Loumaye: None. Rationale: Our study aims to determine whether myostatin is a biomarker of muscle mass in cancer cachexia and obesity. Methods: The ACTICA study included cancer patients with and without cachexia. The MYDIASECRET study included obese patients evaluated before and 3 months after bariatric surgery. Body composition was assessed using bioelectrical impedance analysis (BIA101 device, Akern). Skeletal muscle mass (SMM) and appendicular SMM (ASMM) were calculated from Janssen’s and Sergi’s equations, respectively. Results were expressed as indexes (kg/m²). Myostatin plasma concentrations were determined using ELISA. Spearman’s coefficient was used to correlate muscle mass indexes and myostatin. Results: The ACTICA study included 143 patients of whom 70 with cachexia. SMM index (SMMI) and ASMM index (ASMMI) were lower in patients with cachexia compared to those without cachexia (SMMI: 8.0 kg/m² [6.7-9.5] vs 9.0 kg/m² [7.8-10.1], p=0.004; ASMMI: 6.2 kg/m² [5.5-7.1] vs 7.2 kg/m² [6.4-7.8], pppppppp=0.002) and after surgery (R=0.435, pp=0.023). Conclusion: Myostatin is positively correlated with muscle mass indexes in different conditions, suggesting its potential role as a biomarker of muscle mass. Presentation: Saturday, June 17, 2023